Terminology Service for NFDI4Health
JSON

Inalimarev

Go to external page http://purl.obolibrary.org/obo/NCIT_C29317

A cancer vaccine comprised of a recombinant vaccinia viral vector encoding the carcinoembryonic antigen (CEA), MUC-1 (mucin-1), a transmembrane glycoprotein secreted by glandular tissues, and TRICOM, comprised of the three co-stimulatory molecule transgenes B7-1, ICAM-1 and LFA-3. Upon administration, inalimarev may enhance CEA and MUC-1 presentation to antigen presenting cells (APC) and may activate a cytotoxic T lymphocyte (CTL) response against CEA- and MUC-1-expressing tumor cells. [ ]

Term info

Label

Inalimarev

Synonyms
  • Inalimarev
  • PANVAC-V
  • Vaccinia-CEA-MUC1-TRICOM Vaccine
  • inalimarev
  • rVaccinia-CEA(D609)/MUC1(L93)/TRICOM Vaccine
  • recombinant vaccinia-CEA-MUC-1-TRICOM vaccine
Subsets

NCIT_C116978, NCIT_C128784, NCIT_C116977, NCIT_C157711, NCIT_C157712

ALT DEFINITION

A cancer vaccine made with a form of vaccinia virus that does not cause disease in humans. It is being studied in the treatment of some types of cancer. The virus is changed in the laboratory to make human proteins, including the tumor markers called CEA and MUC-1, that may help immune cells in the body kill tumor cells.

CAS Registry

685563-13-7

Display Name

Inalimarev

Has Target

http://purl.obolibrary.org/obo/NCIT_C2407, http://purl.obolibrary.org/obo/NCIT_C25159

Legacy Concept Name

rVaccinia-CEA_D609_MUC1_L93_TRICOM

NSC Code

727026

Preferred Name

Inalimarev

Semantic Type

Pharmacologic Substance, Virus

UMLS CUI

C1541349

code

C29317